78 related articles for article (PubMed ID: 17982652)
1. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Poujol S; Pinguet F; Ychou M; Abderrahim AG; Duffour J; Bressolle FM
Oncol Rep; 2007 Dec; 18(6):1613-321. PubMed ID: 17982652
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
Poujol S; Bressolle F; Duffour J; Abderrahim AG; Astre C; Ychou M; Pinguet F
Cancer Chemother Pharmacol; 2006 Sep; 58(3):292-305. PubMed ID: 16369821
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Vénat-Bouvet L; Saint-Marcoux F; Lagarde C; Peyronnet P; Lebrun-Ly V; Tubiana-Mathieu N
Anticancer Drugs; 2007 Sep; 18(8):977-80. PubMed ID: 17667606
[TBL] [Abstract][Full Text] [Related]
7. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Chabot GG
Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Deyme L; Barbolosi D; Mbatchi LC; Tubiana-Mathieu N; Ychou M; Evrard A; Gattacceca F
Cancer Chemother Pharmacol; 2021 Aug; 88(2):247-258. PubMed ID: 33912999
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
[TBL] [Abstract][Full Text] [Related]
14. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Mathijssen RH; van Alphen RJ; de Jonge MJ; Verweij J; de Bruijn P; Loos WJ; Nooter K; Vernillet L; Stoter G; Sparreboom A
Anticancer Drugs; 1999 Jan; 10(1):9-16. PubMed ID: 10194542
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Mathijssen RH; Verweij J; Loos WJ; de Bruijn P; Nooter K; Sparreboom A
Br J Cancer; 2002 Jul; 87(2):144-50. PubMed ID: 12107833
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
19. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT
J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
